Cutaneous malignancies in chronic lymphocytic leukemia.

Zilberg C, Ferguson AL, Lyons JG, Gupta R, Fuller SJ, Damian DL. The Journal of Dermatology, 51, no. 3, (Jan 31 2024): 353-64, doi:https://doi.org/10.1111/1346-8138.17126.

Abstract

Chronic lymphocytic leukemia (CLL) is a common lymphoid malignancy that is associated with an increased risk of developing cutaneous malignancies. Clinical outcomes for these malignancies, including melanoma and keratinocyte cancers (KC), are worse for patients with CLL. Individuals with CLL develop an immunodeficiency of both the adaptive and innate immune system, which plays a role in the increased prevalence of skin cancers. This review focuses on the complex interplay between genetics, immunity, and pathogens that influence the cellular composition and biology of skin tumors and their microenvironment in CLL patients, and in comparison with other chronic hematological malignancies. It is paramount for dermatologists to be aware of the association between CLL (and chronic hematological malignancies more broadly) and cutaneous malignancies. This is a high-risk population who require regular and vigorous dermatologic follow-up.